Eikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD

Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative…

Read MoreEikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD